A Multi-Institutional, Prospective, Randomized, Double-blinded, Phase II Trial of the Tumor Lysate, Particle-Only (TLPO) Vaccine Compared to Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine (TLPLDC) to Prevent Recurrence in High-risk Melanoma Patients
Conferences